These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
411 related articles for article (PubMed ID: 24625369)
1. Hydrophobic mutations in buried polar residues enhance HIV-1 gp41 N-terminal heptad repeat-C-terminal heptad repeat interactions and C-peptides' anti-HIV activity. Zheng B; Wang K; Lu L; Yu F; Cheng M; Jiang S; Liu K; Cai L AIDS; 2014 Jun; 28(9):1251-60. PubMed ID: 24625369 [TBL] [Abstract][Full Text] [Related]
2. The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors. Zhu Y; Ding X; Yu D; Chong H; He Y J Virol; 2019 Dec; 94(1):. PubMed ID: 31619552 [TBL] [Abstract][Full Text] [Related]
3. Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors. Geng X; Liu Z; Yu D; Qin B; Zhu Y; Cui S; Chong H; He Y Viruses; 2019 Jul; 11(7):. PubMed ID: 31277353 [TBL] [Abstract][Full Text] [Related]
4. ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer. Yu F; Lu L; Liu Q; Yu X; Wang L; He E; Zou P; Du L; Sanders RW; Liu S; Jiang S Biochim Biophys Acta; 2014 May; 1838(5):1296-305. PubMed ID: 24388952 [TBL] [Abstract][Full Text] [Related]
5. Molecular dynamics studies of the inhibitor C34 binding to the wild-type and mutant HIV-1 gp41: inhibitory and drug resistant mechanism. Ma X; Tan J; Su M; Li C; Zhang X; Wang C PLoS One; 2014; 9(11):e111923. PubMed ID: 25393106 [TBL] [Abstract][Full Text] [Related]
6. HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides. Liu S; Jing W; Cheung B; Lu H; Sun J; Yan X; Niu J; Farmar J; Wu S; Jiang S J Biol Chem; 2007 Mar; 282(13):9612-9620. PubMed ID: 17276993 [TBL] [Abstract][Full Text] [Related]
7. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors. Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416 [TBL] [Abstract][Full Text] [Related]
8. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain. Lu L; Tong P; Yu X; Pan C; Zou P; Chen YH; Jiang S Biochim Biophys Acta; 2012 Dec; 1818(12):2950-7. PubMed ID: 22867851 [TBL] [Abstract][Full Text] [Related]
9. Stabilizing the native trimer of HIV-1 Env by destabilizing the heterodimeric interface of the gp41 postfusion six-helix bundle. Kesavardhana S; Varadarajan R J Virol; 2014 Sep; 88(17):9590-604. PubMed ID: 24920800 [TBL] [Abstract][Full Text] [Related]
10. Conserved residue Lys574 in the cavity of HIV-1 Gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry. He Y; Liu S; Jing W; Lu H; Cai D; Chin DJ; Debnath AK; Kirchhoff F; Jiang S J Biol Chem; 2007 Aug; 282(35):25631-9. PubMed ID: 17616522 [TBL] [Abstract][Full Text] [Related]
11. Structural and Thermodynamic Analysis of HIV-1 Fusion Inhibition Using Small gp41 Mimetic Proteins. Jurado S; Cano-Muñoz M; Morel B; Standoli S; Santarossa E; Moog C; Schmidt S; Laumond G; Cámara-Artigas A; Conejero-Lara F J Mol Biol; 2019 Aug; 431(17):3091-3106. PubMed ID: 31255705 [TBL] [Abstract][Full Text] [Related]
12. Peptide and non-peptide HIV fusion inhibitors. Jiang S; Zhao Q; Debnath AK Curr Pharm Des; 2002; 8(8):563-80. PubMed ID: 11945159 [TBL] [Abstract][Full Text] [Related]
13. Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors. He Y; Cheng J; Li J; Qi Z; Lu H; Dong M; Jiang S; Dai Q J Virol; 2008 Jul; 82(13):6349-58. PubMed ID: 18417584 [TBL] [Abstract][Full Text] [Related]
14. Addition of artificial salt bridge by Ile646Lys mutation in gp41 coiled-coil domain regulates 6-helical bundle formation. Zhao L; Hu ZW; Tong P; Chen YX; Zhao YF; Li YM Bioorg Med Chem Lett; 2013 May; 23(9):2727-32. PubMed ID: 23522564 [TBL] [Abstract][Full Text] [Related]
15. A multi-functional peptide as an HIV-1 entry inhibitor based on self-concentration, recognition, and covalent attachment. Zhao L; Tong P; Chen YX; Hu ZW; Wang K; Zhang YN; Zhao DS; Cai LF; Liu KL; Zhao YF; Li YM Org Biomol Chem; 2012 Aug; 10(32):6512-20. PubMed ID: 22760295 [TBL] [Abstract][Full Text] [Related]
16. Extremely Thermostabilizing Core Mutations in Coiled-Coil Mimetic Proteins of HIV-1 gp41 Produce Diverse Effects on Target Binding but Do Not Affect Their Inhibitory Activity. Cano-Muñoz M; Cesaro S; Morel B; Lucas J; Moog C; Conejero-Lara F Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33921495 [TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of a subpocket on the N-trimer of HIV-1 Gp41: implication for viral entry and drug target. Qiu Z; Chong H; Yao X; Su Y; Cui S; He Y AIDS; 2015 Jun; 29(9):1015-24. PubMed ID: 26125136 [TBL] [Abstract][Full Text] [Related]
18. Adding an Artificial Tail-Anchor to a Peptide-Based HIV-1 Fusion Inhibitor for Improvement of Its Potency and Resistance Profile. Su S; Ma Z; Hua C; Li W; Lu L; Jiang S Molecules; 2017 Nov; 22(11):. PubMed ID: 29156603 [TBL] [Abstract][Full Text] [Related]
19. Identification of critical antibody-binding sites in the HIV-1 gp41 six-helix bundle core as potential targets for HIV-1 fusion inhibitors. Li J; Chen X; Huang J; Jiang S; Chen YH Immunobiology; 2009; 214(1):51-60. PubMed ID: 19159827 [TBL] [Abstract][Full Text] [Related]
20. Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides. Shu W; Liu J; Ji H; Radigen L; Jiang S; Lu M Biochemistry; 2000 Feb; 39(7):1634-42. PubMed ID: 10677212 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]